Vivos Therapeutics Reports Widening Q1 Loss and Increased Cash Burn Amid Ongoing Nasdaq Delisting Risk
VVOS is trading near its 52-week low of $0.57 (0.2% above the low).
Summary
Vivos Therapeutics reported a significantly wider net loss and increased cash burn in Q1 2026, reiterating a 'going concern' warning and ongoing Nasdaq delisting risk despite recent equity raises.
Key Events · Earnings and Guidance · VVOS
-
Net Loss Widens Significantly
Net loss for Q1 2026 more than doubled to $7.75 million, compared to $3.86 million in Q1 2025.
-
Increased Cash Burn
Net cash used in operating activities increased to $6.01 million in Q1 2026, up from $3.80 million in Q1 2025.
-
Going Concern Warning Reiterated
The company explicitly states its $2.11 million in cash and cash equivalents as of March 31, 2026, is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.
-
Ongoing Nasdaq Delisting Threat
Vivos Therapeutics received a Nasdaq notice on April 17, 2026, for non-compliance with the minimum stockholders' equity requirement ($2.5 million), with a plan to regain compliance due by June 1, 2026.
Analysis · VVOS · Industrial Applications And Services
Vivos Therapeutics' Q1 2026 results highlight a critical financial situation, with net losses doubling and cash burn significantly increasing year-over-year. Despite a 70% revenue increase, the company explicitly states its cash is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern. The company also faces an active Nasdaq delisting threat due to negative stockholders' equity, requiring a compliance plan by June 1, 2026. Recent equity financings provided temporary capital but did not resolve the underlying financial instability or Nasdaq deficiency.
At the time of this filing, VVOS was trading at $0.57 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.57 to $7.95. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.